Patents by Inventor Jennifer Xavier

Jennifer Xavier has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • SMALL MOLECULE INHIBITORS OF SALT INDUCIBLE KINASES
    Publication number: 20240174662
    Abstract: Small molecule inhibitors of salt inducible kinases (SIKs) are provided. In particular, compounds of formula (II) and compounds of formula (III), and tautomers, stereoisomers, pharmaceutically acceptable salts and solvates thereof are provided. Also provided are pharmaceutical compositions containing the compounds, methods of preparing the compounds, and methods of using the compounds for inhibiting SIKs, such as SIK1 and SIK2, and methods of treating diseases mediated by SIKs.
    Type: Application
    Filed: January 31, 2022
    Publication date: May 30, 2024
    Inventors: Genesis M. BACANI, Wenying CHAI, De Michael CHUNG, Steven D. GOLDBERG, Gavin HIRST, Virendar KAUSHIK, Eduardo V. MERCADO-MARIN, Donald RAYMOND, Mark SEIERSTAD, Russel C. SMITH, Thomas SUNDBERG, Mark S. TICHENOR, Jennifer D. VENABLE, Jianmei WEI, Ramnik XAVIER
  • SMALL MOLECULE INHIBITORS OF SALT INDUCIBLE KINASES
    Publication number: 20240158392
    Abstract: Small molecule inhibitors of salt inducible kinases (SIKs) are provided. In particular, compounds of formula (I), and tautomers, stereoisomers, pharmaceutically acceptable salts and solvates thereof are provided. Also provided are pharmaceutical compositions containing the compounds, methods of preparing the compounds, and methods of using the compounds for inhibiting SIKs, such as SIK1 and SIK2, and methods of treating diseases mediated by SIKs.
    Type: Application
    Filed: January 31, 2022
    Publication date: May 16, 2024
    Inventors: Genesis M. BACANI, Wenying CHAI, De Michael CHUNG, Steven D. GOLDBERG, Gavin HIRST, Virnedar KAUSHIK, Eduardo V. MERCADO-MARIN, Donald RAYMOND, Mark SEIERSTAD, Russel C. SMITH, Thomas SUNDBERG, Mark S. TICHENOR, Jennifer D. VENABLE, Jianmei WEI, Ramnik XAVIER, Helena C. STEFFENS
  • Substrate processing systems including gas delivery system with reduced dead legs
    Patent number: 11959172
    Abstract: A gas delivery system includes a 2-port valve including a first valve located between a first port and a second port. A 4-port valve includes a first node connected to a first port and a second port. A bypass path is located between the third port and the fourth port. A second node is located along the bypass path. A second valve is located between the first node and the second node. A manifold block defines gas flow channels configured to connect the first port of the 4-port valve to a first inlet, configured to connect the second port of the 4-port valve to the first port of the 2-port valve, the third port of the 4-port valve to a second inlet, the second port of the 2-port valve to a first outlet, and the fourth port of the 4-port valve to a second outlet.
    Type: Grant
    Filed: May 12, 2023
    Date of Patent: April 16, 2024
    Assignee: LAM RESEARCH CORPORATION
    Inventors: Ramesh Chandrasekharan, Antonio Xavier, Frank Loren Pasquale, Ryan Blaquiere, Jennifer Leigh Petraglia, Meenakshi Mamunuru
  • Methods of treating cancer using compounds containing a vascular disrupting agent
    Patent number: 10912839
    Abstract: The present invention relates to prodrugs of vascular disrupting agents comprising a vascular disrupting agent (VDA) associated with a MMP proteolytic cleavage site and to the use of such prodrugs in the targeted treatment of cancer.
    Type: Grant
    Filed: March 1, 2018
    Date of Patent: February 9, 2021
    Assignee: ELLIPSES PHARMA LIMITED
    Inventors: Robert Falconer, Jason Gill, Jennifer Xavier, Paul Loadman, Michael Bibby, Laurence Patterson
  • METHODS OF TREATING CANCER USING COMPOUNDS CONTAINING A VASCULAR DISRUPTING AGENT
    Publication number: 20200316212
    Abstract: The present invention relates to prodrugs of vascular disrupting agents comprising a vascular disrupting agent (VDA) associated with a MMP proteolytic cleavage site and to the use of such prodrugs in the targeted treatment of cancer.
    Type: Application
    Filed: June 19, 2020
    Publication date: October 8, 2020
    Inventors: Robert Andrew Falconer, Jason Gill, Jennifer Xavier, Paul Loadman, Michael Bibby, Laurence Patterson
  • Compounds containing a vascular disrupting agent
    Patent number: 10556014
    Abstract: The present invention relates to compounds, and pharmaceutically acceptable salts thereof, comprising a vascular disrupting agent (VDA) associated and a MMP proteolytic cleavage site. The compounds are useful in the treatment of cancer.
    Type: Grant
    Filed: March 16, 2018
    Date of Patent: February 11, 2020
    Assignee: ELLIPSES PHARMA LIMITED
    Inventors: Jason Gill, Paul Loadman, Rob Falconer, Laurence Patterson, Jennifer Xavier, Michael Bibby
  • COMPOUNDS CONTAINING A VASCULAR DISRUPTING AGENT
    Publication number: 20180228910
    Abstract: The present invention relates to compounds, and pharmaceutically acceptable salts thereof, comprising a vascular disrupting agent (VDA) associated and a MMP proteolytic cleavage site. The compounds are useful in the treatment of cancer.
    Type: Application
    Filed: March 16, 2018
    Publication date: August 16, 2018
    Inventors: Jason Gill, Paul Loadman, Rob Falconer, Laurence Patterson, Jennifer Xavier, Michael Bibby
  • Methods Of Treating Cancer Using Compounds Containing A Vascular Disrupting Agent
    Publication number: 20180177886
    Abstract: The present invention relates to prodrugs of vascular disrupting agents comprising a vascular disrupting agent (VDA) associated with a MMP proteolytic cleavage site and to the use of such prodrugs in the targeted treatment of cancer.
    Type: Application
    Filed: March 1, 2018
    Publication date: June 28, 2018
    Inventors: Robert Falconer, Jason Gill, Jennifer Xavier, Paul Loadman, Michael Bibby, Laurence Patterson
  • Compounds containing a vascular disrupting agent
    Patent number: 9956296
    Abstract: The present invention relates to compounds, and pharmaceutically acceptable salts thereof, comprising a vascular disrupting agent (VDA) associated and a MMP proteolytic cleavage site. The compounds are useful in the treatment of cancer.
    Type: Grant
    Filed: May 6, 2016
    Date of Patent: May 1, 2018
    Assignee: INCANTHERA LTD
    Inventors: Jason Gill, Paul Loadman, Rob Falconer, Laurence Patterson, Jennifer Xavier, Michael Bibby
  • Methods of treating cancer using compounds containing a vascular disrupting agent
    Patent number: 9937267
    Abstract: The present invention relates to prodrugs of vascular disrupting agents comprising a vascular disrupting agent (VDA) associated with a MMP proteolytic cleavage site and to the use of such prodrugs in the targeted treatment of cancer.
    Type: Grant
    Filed: October 19, 2016
    Date of Patent: April 10, 2018
    Assignee: Incanthera Ltd
    Inventors: Robert Andrew Falconer, Jason Gill, Jennifer Xavier, Paul Loadman, Michael Bibby, Laurence Patterson
  • Methods Of Treating Cancer Using Compounds Containing A Vascular Disrupting Agent
    Publication number: 20170266307
    Abstract: The present invention relates to prodrugs of vascular disrupting agents comprising a vascular disrupting agent (VDA) associated with a MMP proteolytic cleavage site and to the use of such prodrugs in the targeted treatment of cancer.
    Type: Application
    Filed: October 19, 2016
    Publication date: September 21, 2017
    Inventors: Robert Andrew Falconer, Jason Gill, Jennifer Xavier, Paul Loadman, Michael Bibby, Laurence Patterson
  • COMPOUNDS CONTAINING A VASCULAR DISRUPTING AGENT
    Publication number: 20160243252
    Abstract: The present invention relates to compounds, and pharmaceutically acceptable salts thereof, comprising a vascular disrupting agent (VDA) associated and a MMP proteolytic cleavage site. The compounds are useful in the treatment of cancer.
    Type: Application
    Filed: May 6, 2016
    Publication date: August 25, 2016
    Inventors: Jason Gill, Paul Loadman, Rob Falconer, Laurence Patterson, Jennifer Xavier, Michael Bibby
  • Compounds containing a vascular disrupting agent
    Patent number: 9358303
    Abstract: The present invention relates to compounds, and pharmaceutically acceptable salts thereof, comprising a vascular disrupting agent (VDA) associated and a MMP proteolytic cleavage site. The compounds are useful in the treatment of cancer.
    Type: Grant
    Filed: December 17, 2013
    Date of Patent: June 7, 2016
    Assignee: Incanthera Ltd
    Inventors: Jason Gill, Paul Loadman, Rob Falconer, Laurence Patterson, Jennifer Xavier, Michael Bibby
  • Compounds
    Publication number: 20150196658
    Abstract: The present invention relates to prodrugs of vascular disrupting agents comprising a vascular disrupting agent (VDA) associated with a MMP proteolytic cleavage site and to the use of such prodrugs in the targeted treatment of cancer.
    Type: Application
    Filed: November 25, 2014
    Publication date: July 16, 2015
    Inventors: Robert Andrew Falconer, Jason Gill, Jennifer Xavier, Paul Loadman, Michael Bibby, Laurence Patterson